Zhong Zheng Wang·2025-08-26 13:57Core Viewpoint - 凯莱英 reported a strong financial performance for the first half of 2025, with significant revenue and profit growth driven by operational efficiency and market expansion efforts [1][2]. Group 1: Financial Performance - The company achieved total revenue of 3.188 billion yuan, representing an 18.20% year-on-year increase, with Q2 revenue of 1.647 billion yuan, up 6.87% from Q1 [1]. - Net profit attributable to shareholders reached 617 million yuan, a 23.71% increase, outpacing revenue growth by 5.51 percentage points [1]. Group 2: Market Expansion - In 2025, the company added over 150 new CDMO business clients, expanding its customer base significantly [2]. - Revenue from the U.S. market was 1.789 billion yuan, up 0.45%, while domestic revenue was 713 million yuan, up 3.44%, and European revenue exceeded 200% growth, reaching 548 million yuan [2]. - Revenue from large pharmaceutical companies was 1.508 billion yuan, a 14.68% increase, while revenue from small and medium-sized pharmaceutical companies was 1.680 billion yuan, growing by 21.55% [2]. Group 3: R&D Investment - The company invested 286 million yuan in R&D, accounting for 8.96% of total revenue, focusing on continuous reaction and biocatalysis technologies [3]. - As of the end of the reporting period, the company held 538 authorized patents, including 423 domestic and 115 international patents, with significant contributions in synthetic biology and continuous reaction technology [3].